Back Hepatitis C

Hepatitis C

European Regulators Give Positive Opinion on Daclatasvir for Hepatitis C

Bristol-Myers Squibb announced this week that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its hepatitis C virus (HCV) NS5A inhibitor daclatasvir, which has been given the brand name Daklinza.

alt

AbbVie's 3D Hepatitis C Combo Gets Priority Review in U.S. and Europe

AbbVie's all-oral 3-drug combination regimen for genotype 1 chronic hepatitis C has been granted priority review status by the U.S. Food and Drug Administration (FDA), putting it on track for approval by the end of the year. In related news, the company announced last week that Marketing Authorization Applications for the 3D regimen have been validated and are under accelerated assessment by the European Medicines Agency (EMA), with a decision expected in early 2015.

alt

Medicare Will Cover Hepatitis C Screening for Baby Boomers and People at Risk

The Centers for Medicare and Medicaid Services (CMS) announced this week that Medicare will cover hepatitis C virus (HCV) screening for adults born between 1945 and 1965, as well as others considered at risk, when requested by a primary care physician or other providers within a primary care setting.

alt

Sofosbuvir/Ledipasvir Cures 100% of Genotype 1 Hepatitis C Patients in Japanese Study

All treatment-naive and previously treated participants using a combination pill containing Gilead Science's hepatitis C virus (HCV) polymerase inhibitor sofosbuvir (Sovaldi) and NS5A inhibitor ledipasvir, without ribavirin, for 12 weeks achieved sustained virological response in a Phase 3 study in Japan, where most hepatitis C patients have HCV genotype 1b.

alt

Hepatitis C Cascade Studies Show Gaps in Testing and Treatment

About half of people with hepatitis C are aware of their infection but less than 10% have been successfully treated and achieved sustained virological response, according to a meta-analysis presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2014). A related study found that among HIV/HCV coinfected people, 40% had been referred to hepatitis C care but only 4% were cured.

alt

Daclatasvir + Asunaprevir Is Highly Effective Against Hepatitis C Genotype 1b

An all-oral combination of daclatasvir plus asunaprevir, without pegylated interferon or ribavirin, cured 87% of genotype 1b patients who were ineligible for or could not tolerate interferon and 81% of prior non-responders in a Japanese study published in the June 2014 edition of Hepatology.

alt

CROI 2014: How Fast Does Fibrosis Progress in Acute Hepatitis C Patients with and without HIV?

Liver disease was found to progress slowly in studies of both HIV negative people with newly acquired hepatitis C virus (HCV) and HIV/HCV coinfected people with acute HCV, according to a pair of studies presented at the recent Conference on Retroviruses and Opportunistic Infections.

alt

HCV Drug Development: Merck Acquires Idenix, FDA Lifts Sovaprevir Hold

Merck this week announced that it will purchase Idenix, a specialty biopharmaceutical company developing several hepatitis C virus (HCV) drug candidates. In related news, Achillion announced that the U.S. Food and Drug Administration (FDA) has lifted a clinical hold on one of its drugs and a clinical trial of another is now underway.

alt

Studies Shed Light on Hepatitis C Virus Sexual Transmission among Gay Men

Hepatitis C virus (HCV) transmission among HIV positive gay men has leveled off in Amsterdam -- one of the first cities with an outbreak of apparently sexually transmitted HCV infection -- and it continues to be rare among HIV negative men who have sex with men, according to recent studies. Other research looked at HCV sexual transmission among HIV positive and negative men in Switzerland, and at the association between HCV viral load in blood and semen.

alt